



• Dermatology
beyond the skin

SPONSORSHIP AGREEMENT

BETWEEN

LEO Pharma A/S

and

Eksemforeningen

TABLE OF CONTENTS

1. **PURPOSE** 3

2. **OBLIGATIONS OF THE PARTIES** 3

3. **PLACE AND TIME**..... 4

4. **FINANCIAL COMMITMENT** 4

5. **NON-FINANCIAL COMMITMENT** 5

6. **TRANSPARENCY** 5

7. **USE OF THE ORGANIZATION’S LOGO OR THE LEO PHARMA LOGO**..... 6

8. **INDEPENDENCE AND CONFLICT OF INTEREST** 6

9. **ANTI-BRIBERY AND THIRD PARTY COMPLIANCE**..... 6

10. **FORCE MAJEURE** 7

11. **TERM AND TERMINATION**..... 7

12. **LAW AND VENUE**..... 7

13. **SIGNATURES AND COMPLETENESS OF THE AGREEMENT**..... 8

LIST OF SCHEDULES

SCHEDULE A:	REQUEST LETTER
SCHEDULE B:	BUDGET

This Sponsorship Agreement (the “**Agreement**”) effective as of the date of the last signature on the Agreement (the “**Effective Date**”) is made and entered into by and between:

- (1) **LEO Pharma A/S**, a company organised and existing under the laws of Denmark and having its registered office at Industriparken 55, 2750 Ballerup, Denmark, with its company registration no. 56759514 (“**LEO Pharma**”), and
- (2) **Eksemforeningen**, an organization existing under the laws of Denmark and having its registered office at Hvidovrevej 108, 1. tv., 2650 Hvidovre, Denmark with registration no. 33736665 (the “**Organization**”),

LEO Pharma and the Organization hereinafter each referred to as a “**Party**” and collectively referred to as the “**Parties**”.

WHEREAS:

- (A) LEO Pharma is a research-based pharmaceutical company that develops, manufactures and markets pharmaceutical products to patients within dermatology and thrombosis;
- (B) The Organization is a working with supporting, education and information for patients and caregivers diagnosed with Atopic Dermatitis
- (C) The Organization has requested support from LEO to support the project as listed in schedule A;
- (D) LEO Pharma agrees to support the Organization to increase awareness, put focus and attention on Atopic Dermatitis as described in schedule A

NOW THEREFORE, the Parties have agreed as follows:

1. PURPOSE

- 1.1. The purpose of this Agreement is to describe the terms and conditions for the funding to provide economic support made by LEO Pharma to the Organization in connection with the request to support the activities planned for World Eczema Day 2026, as described in Schedule A (“**Project**”).

2. OBLIGATIONS OF THE PARTIES

- 2.1. LEO Pharma undertakes during the term of the Agreement to provide Funding to the Project.
- 2.2. The Organization has provided LEO Pharma with a request letter (attached as **Schedule A**) and a full breakdown of the

Project budget (attached as **Schedule B**), to be covered by the Funding from LEO Pharma.

- 2.3. The Organization represents and warrants to comply with any and all applicable laws, regulations and industry ethical codes in force from time to time in connection with the Project including, but not limited to, the codes listed in Clause 2.4.
- 2.4. The Organization acknowledges that LEO Pharma must comply with applicable industry ethical codes including but not limited to:
- the International Federation of Pharmaceutical Manufactures and Associations (IFPMA) Code of Practice;
 - The European Federation of Pharmaceutical Industries and Associations (EFPIA) Code of Practice
 - the Danish Ethical Committee for the Pharmaceutical Industry's (ENLI) Code of Practice on Promotion etc., of Medicinal Products aimed at Healthcare Professionals (Reklamekodekset)
 - the Danish Ethical Committee for the Pharmaceutical Industry (ENLI) Ethical Rules for Collaboration between Patient Organizations, etc., and the Pharmaceutical Industry; and
 - any other applicable national industry Code of Practice regarding the relationship between the pharmaceutical industry and healthcare professionals ("HCPs") and/or healthcare organizations ("HCOs");
- 2.5. The Organization undertakes to ensure that the Funding received from LEO Pharma will be spent solely in connection with the Project, in a reasonable manner and in accordance with this Agreement and the ethical codes listed in Clause 2.4. The Funding must solely be spent on the professional/scientific activities of the Project. This entails, inter alia, that the Organization confirms that all elements of the Project, for example the venue, are reasonable and in no way extravagant. The Organization also confirms that no elements of entertainment are contained in the Project and that no gifts will be provided to the participating healthcare professionals during the course of the Project.
- 2.6. Any unused portion of the Funding must be returned to LEO Pharma within thirty (30) days of finalisation of the Project. Upon request from LEO Pharma the Organization must provide documentation for the paid expenses in relation to the Project.
- 2.7. The Organization confirms that it has obtained and will maintain all consents and permissions necessary to conduct its business including the Project.

3. PLACE AND TIME

- 3.1. The Project takes place in Denmark from March 2026 to December 2026.

4. FINANCIAL COMMITMENT

- 4.1. The financial commitment of LEO Pharma under this Agreement shall be 42.000 DKK (the "**Funding**"). The amount is exclusive of VAT.

- 4.2. The Organization shall contact LEO Pharma immediately if any circumstances, including as set out in **Schedule A**, change and LEO Pharma reserves the right to withdraw the Funding if the Project is changed or cancelled prior to completion. The Organization shall return any unused portion thereof, to LEO Pharma within thirty (30) days after of such withdrawal.
- 4.3. The Organization have engaged external consultancy company Decisions (Decisions ApS, Pilehøj 2C, 1.t.v, 3460 Birkerød. CVR 42 57 82 15) and they issue an invoice to LEO Pharma A/S, Att: Kristin Fauskrud, Industriparken 55, 2750 Ballerup, Denmark. Invoice must be sent as a PDF file to knfno@leo-pharma.com, marked "Att: Kristin Fauskrud Eksemforeningen- AD dagen 2026" in the subject line. The invoice must be sent no later than fifteen (15) days after the signature of this Agreement.

The invoice shall include following information:

- LEO Pharma A/S VAT no: DK 56759514
- Full name and address of Organization
- Invoice number and date
- Name of Project
- Invoice currency
- Bank details
- Organization VAT number
- If the Funding is subject to VAT or any other local taxes, any mandatory data in accordance with the provisions of the applicable VAT or tax laws.

Payment terms are end of month plus thirty (30) days from receipt of invoice by LEO Pharma.

5. NON-FINANCIAL COMMITMENT

- 5.1. LEO Pharma will not provide any non-financial commitment under this Agreement.

6. TRANSPARENCY

- 6.1. The Organization must ensure that the receipt of the Funding from LEO Pharma is acknowledged and disclosed in accordance with all applicable laws, regulations and industry ethical codes, including, but not limited to, the codes listed in Clause 2.4. This entails, inter alia, that the Organization shall ensure that (a) the organiser and purpose of the Project appears from the invitation, including any updates to the invite or reminders, to the Project sent out by the Organization, and (b) the invitation states whether the Project has been sponsored by one or more pharmaceutical companies.
- 6.2. The Organization shall publish information that LEO Pharma has provided the Funding on the Organization's website at the latest three (3) days after signing this Agreement.

- 6.3. The Organization accepts that LEO Pharma may notify relevant authorities about the content of this Agreement and publish information regarding this Agreement and the Funding of the Project on the LEO Pharma company website in accordance with applicable laws, regulations and industry ethical codes.
- 6.4. The Organization acknowledges that LEO Pharma and its affiliates, may be required by applicable law, regulation and industry codes, to report, register, disclose and/or publish information about the relationship of the Parties (including any identified indirect recipient of the Funding), payments and/or other transfer of value made to the Organization by or on behalf of LEO Pharma or its affiliates under this Agreement.

7. USE OF THE ORGANIZATION'S LOGO OR THE LEO PHARMA LOGO

- 7.1. The Organization agrees that LEO Pharma may use the Organization's logo or name, and make use of the collaboration with the Organization. Any other use of the Organization's logo must be approved beforehand by the Organization.
- 7.2. LEO Pharma agrees that the Organization may use LEO Pharma's logo or name and make use of the collaboration with the Organization for the purposes mentioned in Clause 6.2. Any other use of the LEO Pharma logo must be approved beforehand by LEO Pharma.

8. INDEPENDENCE AND CONFLICT OF INTEREST

- 8.1. The Parties declare by signing this Agreement that the Organization shall be free to collaborate with other pharmaceutical companies and that LEO Pharma shall be free to collaborate with other Organizations. The Parties further state that their relations shall not involve exclusive rights with respect to specific product or therapeutic areas.
- 8.2. LEO Pharma shall not influence the content of the Project and the organization of the Project is independent of the Funding.
- 8.3. LEO Pharma agrees by signing this Agreement not to impose conditions for the Organization's professional or stakeholder-policy viewpoints. This Agreement shall not be seen as an explicit or implicit agreement that confer an obligation on the Organization to recommend, induce, ordinate, purchase, deliver, sell, administer or in any other way promote the interest of LEO Pharma or its products.

9. ANTI-BRIBERY AND THIRD PARTY COMPLIANCE

- 9.1. The Organization acknowledges that LEO Pharma is committed to maintaining high standards of ethical conduct and will not tolerate the use of bribery or corruption to achieve its business objectives. Thus, the Organization agrees to comply at all times with all applicable anti-bribery laws, rules and regulations (including the UK Bribery Act and the United States Foreign Corrupt Practices Act) when performing its duties under this Agreement.

9.2. The Organization and its representatives shall at all times conform to the Sustainability Standards for LEO Pharma Business Partners (“**Sustainability Standards**”) as amended from time to time. The latest effective version of the Sustainability Standards are available at www.leo-pharma.com/thirdparty. Upon request, the Organization shall provide information on its level of compliance with the Sustainability Standards so that LEO Pharma can assess whether the Organization actually complies with these. The Organization shall at all times and promptly take all appropriate steps to resolve and correct any identified non-conformity. Any breach of Clauses 9.1-9.2 is considered material and shall, without limiting any other right or remedy available, entitle LEO Pharma to terminate this Agreement in whole or in part with immediate effect.

10. FORCE MAJEURE

10.1. Either Party shall be excused from performing its obligations under this Agreement if its performance is delayed or prevented by any cause beyond such Party’s reasonable control and which could not have reasonably been foreseen by such Party on the date on which the Party undertook its obligations. Relevant causes for excuse include, without limitation, terrorist acts, fires or explosions, civil strifes, riots, natural disasters, strikes and labour disturbances at national level or generally including labour not employed by the affected Party, wars, hostilities (whether war be declared or not), sabotages, embargos or government actions. Performance shall be excused only to the extent of and during the reasonable continuance of such disability.

11. TERM AND TERMINATION

11.1. This Agreement shall come into force on the day of the last signature to the Agreement and shall, unless terminated earlier, remain in force until the Project has been completed which date the Agreement shall be terminated automatically.

11.2. If the Organization breaches any of its obligations under this Agreement, LEO Pharma may terminate the Agreement with immediate effect and be entitled to seek other legal redress under Danish law for breach of agreement, including a claim for compensation irrespective of whether the Agreement has been terminated.

11.3. Upon expiration or termination of this Agreement for any reason Clauses 6, 9 and 12 and such other Clauses that by their nature are intended to survive termination, shall survive the termination of this Agreement.

12. LAW AND VENUE

12.1. This Agreement shall be governed by the laws of Denmark without regard to the conflict of laws provisions.

12.2. In the event of any dispute arising out of or relating to any provision of this Agreement, the Parties shall try to settle any such dispute amicably on a good faith basis. If the Parties are unable to solve the dispute within reasonable time, the dispute shall be brought before the city court of Glostrup, Denmark, as the court of first instance.

13. SIGNATURES AND COMPLETENESS OF THE AGREEMENT

13.1. This Agreement constitutes the entire agreement between the Parties relating to the Project and no other express terms, written or oral, shall be incorporated into this Agreement. In case of any contradictions between this Agreement and any of its schedules, this Agreement shall prevail.

13.2. The Agreement may be executed in one or more counterparts, each of which shall be an original and all of which shall constitute together the same document. The Parties agree that the execution of this Agreement by standard industry signature software and/or by exchanging PDF signatures shall have the same legal force and effect as the exchange of original signatures.

Accepted and agreed:

Atopisk Eksem Forening

LEO Pharma A/S

Date: _____

Date: _____

Signature:  Digitally signed by Anne Skov Vastrup
Reason: Accepteret og Enig
Date: 2025-11-24 12:36:31+01:00

Signature:  Digitally signed by Verhaug, Anja Cecilie
Reason: Accepteret og Enig
Date: 2025-11-24 11:16:40+01:00

Name: Anne Skov Vastrup

Name: Anja Verhaug

Title: Formand

Title: General Manager Nordic

Schedule A – Request Letter



LEO Pharma Nordic
Industriparken 55
2750 Ballerup
Att.: Kristin Fauskrud

Kokkedal den 13. november 2025

Ansøgning om støtte til Christiansborg-rundbordsmøde om behandlingsgaranti mv.

Rundbordsmøde/høring på Christiansborg

I forbindelse med Sundhedsreformen er der indført behandlingsgaranti hos praktiserende speciallæger såvel som en forsøgsordning, hvor biologiske behandlinger flyttes fra hospitaler til praktiserende speciallæger.

Udfordringen er dog, at behandlingsgarantien skal opnås ved at skabe større kapacitet hos eksisterende speciallæger samt, at der først fremsættes lovforslag om behandlingsgarantien i 2026.

Ved rundbordsmøde i september 2025 var der god og meget konstruktiv dialog om mulighederne for at få det hele til at lykkes. Vi ønsker at følge op på denne dialog med endnu et rundbordsmøde (evt. en høring) på Christiansborg, hvor politikere, embedsmænd, sundhedsfaglige og patienter kan diskutere processen vedr. behandlingsgarantien med udgangspunkt i foreningens forslag.

Schedule B – Budget

Økonomisk anmodning

Vi vil gerne samarbejde med Decisions om rundbordsmøde mv. samt lade dem stå for fakturering og projektstyring i lighed med rundbordsmødet afholdt i 2025 for 168.680 kr. før moms. I beløbet var både rundbordsmøde, hjælp til kronik om behandlingsgarantien (vedhæftet) samt SoMe indeholdt.

I 2026 laver vi enten et lignende rundbordsmøde med kronik og SoMe, eller en høring.

Vi søger støtte hos både AbbVie, Almirall, Galderma, LEO Pharma og Sanofi, og i forhåbning om at fire selskaber har lyst og mulighed for at bakke op, anmoder vi LEO Pharma om 42.000 kr. før moms til projektet

På forhånd mange tak for opbakningen til foreningens arbejde.

Mange hilsner fra
Anne Skov Vastrup, forperson i Eksemforeningen

Eksemforeningen - Lone Gran Laursen - Hvidovrevej 108, 1. tv. - 2650 Hvidovre
info@eksemforeningen.dk - eksemforeningen.dk
Facebook Eksemforeningen - Facebook: gruppe Eksemforeningen - LinkedIn Eksemforeningen








DK AD dagen 2026- rundbordsmøte Christiansborg

Endelig revisionsrapport

2025-11-24


Oprettet:	2025-11-21
Af:	Kristin Fauskrud (KNFNO@LEO-PHARMA.COM)
Status:	Underskrevet
Transaktions-id:	CBJCHBCAABAANDAhbQoItDfblsSE8cwgUYgct5Ms0o1S

Oversigt over "DK AD dagen 2026- rundbordsmøte Christiansborg"

-  Dokument oprettet af Kristin Fauskrud (KNFNO@LEO-PHARMA.COM)
2025-11-21 - 14:48:37 GMT- IP-adresse: 80.203.116.211
-  Dokumentet blev sendt til Anja Verhaug (AVENO@LEO-PHARMA.COM) til underskrivelse
2025-11-21 - 14:52:59 GMT
-  E-mail blev vist af Anja Verhaug (AVENO@LEO-PHARMA.COM)
2025-11-24 - 10:14:47 GMT- IP-adresse: 104.47.51.254
-  Anja Verhaug (AVENO@LEO-PHARMA.COM) godkendte med Adobe Acrobat Sign.
Udfordring: Brugeren åbnede aftalen.
2025-11-24 - 10:15:21 GMT
-  Anja Verhaug (AVENO@LEO-PHARMA.COM) godkendte med Adobe Acrobat Sign.
Udfordring: Brugeren fuldførte underskrivelsesceremonien.
2025-11-24 - 10:16:37 GMT
-  Dokumentet blev underskrevet digitalt af Verhaug), Anja Cecilie (AVENO@LEO-PHARMA.COM)
Årsag til underskrivelse: Accepteret og Enig
Udbyder af skytjeneste: BankID Norway
Certifikatudsteder: Intesi Group Advanced Cloud Signature Short Term CA
Sikkert tidsstempel: 2025-11-24 - 10:16:40 GMT
Tidsstempelleverandør: Adobe Qualified Timestamp TSU8
Underskrivers IP-adresse: 155.137.0.100
-  Dokumentet blev sendt til anne@vastrup.dk til underskrivelse
2025-11-24 - 10:16:42 GMT



Powered by
Adobe
Acrobat Sign

 E-mail blev vist af anne@vastrup.dk

2025-11-24 - 11:27:04 GMT- IP-adresse: 188.177.121.21

 anne@vastrup.dk godkendte med Adobe Acrobat Sign.


Udfordring: Brugeren åbnede aftalen.

2025-11-24 - 11:30:18 GMT

 anne@vastrup.dk godkendte med Adobe Acrobat Sign.

Udfordring: Brugeren fuldførte underskrivelsesceremonien.

2025-11-24 - 11:36:29 GMT

 Dokumentet blev underskrevet digitalt af Anne Skov Vastrup (anne@vastrup.dk)

Årsag til underskrivelse: Accepteret og Enig


Udbyder af skytjeneste: MitID

Certifikatudsteder: Intesi Group Advanced Cloud Signature Short Term CA

Sikkert tidsstempel: 2025-11-24 - 11:36:32 GMT

Tidsstempelleverandør: Adobe Qualified Timestamp TSU8

Underskrivers IP-adresse: 188.177.121.21

 Aftale fuldført.

2025-11-24 - 11:36:31 GMT



Powered by
Adobe
Acrobat Sign